This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Monath, T. P.
Right arrow Articles by Guirakhoo, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monath, T. P.
Right arrow Articles by Guirakhoo, F.

 Previous Article  |  Next Article 

Journal of Virology, February 2000, p. 1742-1751, Vol. 74, No. 4
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Chimeric Yellow Fever Virus 17D-Japanese Encephalitis Virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing in Rhesus Monkeys

T. P. Monath,1,* I. Levenbook,2 K. Soike,3 Z.-X. Zhang,1 M. Ratterree,3 K. Draper,4 A. D. T. Barrett,5 R. Nichols,1 R. Weltzin,1 J. Arroyo,1 and F. Guirakhoo1

OraVax Inc., Cambridge, Massachusetts 021391; 3228 Prestwick Lane, Northbrook, Illinois 600622; Tulane Regional Primate Center, Covington, Louisiana 704333; Sierra Biomedical Inc., Sparks, Nevada 894314; and Department of Pathology, University of Texas Medical Branch, Galveston, Texas 775555

Received 10 September 1999/Accepted 18 November 1999

ChimeriVax-JE is a live, attenuated recombinant virus prepared by replacing the genes encoding two structural proteins (prM and E) of yellow fever 17D virus with the corresponding genes of an attenuated strain of Japanese encephalitis virus (JE), SA14-14-2 (T. J. Chambers et al., J. Virol. 73:3095-3101, 1999). Since the prM and E proteins contain antigens conferring protective humoral and cellular immunity, the immune response to vaccination is directed principally at JE. The prM-E genome sequence of the ChimeriVax-JE in diploid fetal rhesus lung cells (FRhL, a substrate acceptable for human vaccines) was identical to that of JE SA14-14-2 vaccine and differed from sequences of virulent wild-type strains (SA14 and Nakayama) at six amino acid residues in the envelope gene (E107, E138, E176, E279, E315, and E439). ChimeriVax-JE was fully attenuated for weaned mice inoculated by the intracerebral (i.c.) route, whereas commercial yellow fever 17D vaccine (YF-Vax) caused lethal encephalitis with a 50% lethal dose of 1.67 log10 PFU. Groups of four rhesus monkeys were inoculated by the subcutaneous route with 2.0, 3.0, 4.0, and 5.0 log10 PFU of ChimeriVax-JE. All 16 monkeys developed low viremias (mean peak viremia, 1.7 to 2.1 log10 PFU/ml; mean duration, 1.8 to 2.3 days). Neutralizing antibodies appeared between days 6 and 10; by day 30, neutralizing antibody responses were similar across dose groups. Neutralizing antibody titers to the homologous (vaccine) strain were higher than to the heterologous wild-type JE strains. All immunized monkeys and sham-immunized controls were challenged i.c. on day 54 with 5.2 log10 PFU of wild-type JE. None of the immunized monkeys developed viremia or illness and had mild residual brain lesions, whereas controls developed viremia, clinical encephalitis, and severe histopathologic lesions. Immunized monkeys developed significant (>= 4-fold) increases in serum and cerebrospinal fluid neutralizing antibodies after i.c. challenge. In a standardized test for neurovirulence, ChimeriVax-JE and YF-Vax were compared in groups of 10 monkeys inoculated i.c. and analyzed histopathologically on day 30. Lesion scores in brains and spinal cord were significantly higher for monkeys inoculated with YF-Vax. ChimeriVax-JE meets preclinical safety and efficacy requirements for a human vaccine; it appears safer than yellow fever 17D vaccine but has a similar profile of immunogenicity and protective efficacy.

* Corresponding author. Mailing address: OraVax Inc., 38 Sidney Street, Cambridge, MA 02139. Phone: (617) 494-1339. Fax: (617) 494-1741. E-mail: tmonath{at}oravax.com.

Journal of Virology, February 2000, p. 1742-1751, Vol. 74, No. 4
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Levenbook, I., Draper, K., Maximova, O. A., Whitehead, S. S., Murphy, B. R., Pletnev, A. G. (2009). Neuropathogenesis and Neurovirulence of Live Flaviviral Vaccines in Monkeys. J. Virol. 83: 5289-5292 [Full Text]  
  • Lobigs, M., Larena, M., Alsharifi, M., Lee, E., Pavy, M. (2009). Live Chimeric and Inactivated Japanese Encephalitis Virus Vaccines Differ in Their Cross-Protective Values against Murray Valley Encephalitis Virus. J. Virol. 83: 2436-2445 [Abstract] [Full Text]  
  • Maximova, O. A., Ward, J. M., Asher, D. M., St. Claire, M., Finneyfrock, B. W., Speicher, J. M., Murphy, B. R., Pletnev, A. G. (2008). Comparative Neuropathogenesis and Neurovirulence of Attenuated Flaviviruses in Nonhuman Primates. J. Virol. 82: 5255-5268 [Abstract] [Full Text]  
  • Seino, K. K., Long, M. T., Gibbs, E. P. J., Bowen, R. A., Beachboard, S. E., Humphrey, P. P., Dixon, M. A., Bourgeois, M. A. (2007). Comparative Efficacies of Three Commercially Available Vaccines against West Nile Virus (WNV) in a Short-Duration Challenge Trial Involving an Equine WNV Encephalitis Model. CVI 14: 1465-1471 [Abstract] [Full Text]  
  • HIGGS, S., VANLANDINGHAM, D. L., KLINGLER, K. A., MCELROY, K. L., MCGEE, C. E., HARRINGTON, L., LANG, J., MONATH, T. P., GUIRAKHOO, F. (2006). GROWTH CHARACTERISTICS OF CHIMERIVAX-DEN VACCINE VIRUSES IN AEDES AEGYPTI AND AEDES ALBOPICTUS FROM THAILAND. Am J Trop Med Hyg 75: 986-993 [Abstract] [Full Text]  
  • Monath, T. P., Liu, J., Kanesa-Thasan, N., Myers, G. A., Nichols, R., Deary, A., McCarthy, K., Johnson, C., Ermak, T., Shin, S., Arroyo, J., Guirakhoo, F., Kennedy, J. S., Ennis, F. A., Green, S., Bedford, P. (2006). A live, attenuated recombinant West Nile virus vaccine. Proc. Natl. Acad. Sci. USA 103: 6694-6699 [Abstract] [Full Text]  
  • Bonaldo, M. C., Garratt, R. C., Marchevsky, R. S., Coutinho, E. S. F., Jabor, A. V., Almeida, L. F. C., Yamamura, A. M. Y., Duarte, A. S., Oliveira, P. J., Lizeu, J. O. P., Camacho, L. A. B., Freire, M. S., Galler, R. (2005). Attenuation of Recombinant Yellow Fever 17D Viruses Expressing Foreign Protein Epitopes at the Surface. J. Virol. 79: 8602-8613 [Abstract] [Full Text]  
  • Bernardo, L., Yndart, A., Vazquez, S., Morier, L., Guzman, M. G. (2005). Antibody Responses to Asian and American Genotypes of Dengue 2 Virus in Immunized Mice. CVI 12: 361-362 [Abstract] [Full Text]  
  • BRANDLER, S., BROWN, N., ERMAK, T. H., MITCHELL, F., PARSONS, M., ZHANG, Z., LANG, J., MONATH, T. P., GUIRAKHOO, F. (2005). REPLICATION OF CHIMERIC YELLOW FEVER VIRUS-DENGUE SEROTYPE 1-4 VIRUS VACCINE STRAINS IN DENDRITIC AND HEPATIC CELLS. Am J Trop Med Hyg 72: 74-81 [Abstract] [Full Text]  
  • Arroyo, J., Miller, C., Catalan, J., Myers, G. A., Ratterree, M. S., Trent, D. W., Monath, T. P. (2004). ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy. J. Virol. 78: 12497-12507 [Abstract] [Full Text]  
  • Guirakhoo, F., Zhang, Z., Myers, G., Johnson, B. W., Pugachev, K., Nichols, R., Brown, N., Levenbook, I., Draper, K., Cyrek, S., Lang, J., Fournier, C., Barrere, B., Delagrave, S., Monath, T. P. (2004). A Single Amino Acid Substitution in the Envelope Protein of Chimeric Yellow Fever-Dengue 1 Vaccine Virus Reduces Neurovirulence for Suckling Mice and Viremia/Viscerotropism for Monkeys. J. Virol. 78: 9998-10008 [Abstract] [Full Text]  
  • Guirakhoo, F., Pugachev, K., Zhang, Z., Myers, G., Levenbook, I., Draper, K., Lang, J., Ocran, S., Mitchell, F., Parsons, M., Brown, N., Brandler, S., Fournier, C., Barrere, B., Rizvi, F., Travassos, A., Nichols, R., Trent, D., Monath, T. (2004). Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates. J. Virol. 78: 4761-4775 [Abstract] [Full Text]  
  • Harvey, T. J., Liu, W. J., Wang, X. J., Linedale, R., Jacobs, M., Davidson, A., Le, T. T. T., Anraku, I., Suhrbier, A., Shi, P.-Y., Khromykh, A. A. (2004). Tetracycline-Inducible Packaging Cell Line for Production of Flavivirus Replicon Particles. J. Virol. 78: 531-538 [Abstract] [Full Text]  
  • Kojima, A., Yasuda, A., Asanuma, H., Ishikawa, T., Takamizawa, A., Yasui, K., Kurata, T. (2003). Stable High-Producer Cell Clone Expressing Virus-Like Particles of the Japanese Encephalitis Virus E Protein for a Second-Generation Subunit Vaccine. J. Virol. 77: 8745-8755 [Abstract] [Full Text]  
  • Monath, T. P., Arroyo, J., Levenbook, I., Zhang, Z.-X., Catalan, J., Draper, K., Guirakhoo, F. (2002). Single Mutation in the Flavivirus Envelope Protein Hinge Region Increases Neurovirulence for Mice and Monkeys but Decreases Viscerotropism for Monkeys: Relevance to Development and Safety Testing of Live, Attenuated Vaccines. J. Virol. 76: 1932-1943 [Abstract] [Full Text]  
  • Guirakhoo, F., Arroyo, J., Pugachev, K. V., Miller, C., Zhang, Z.-X., Weltzin, R., Georgakopoulos, K., Catalan, J., Ocran, S., Soike, K., Ratterree, M., Monath, T. P. (2001). Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine. J. Virol. 75: 7290-7304 [Abstract] [Full Text]  
  • Hurrelbrink, R. J., McMinn, P. C. (2001). Attenuation of Murray Valley Encephalitis Virus by Site-Directed Mutagenesis of the Hinge and Putative Receptor-Binding Regions of the Envelope Protein. J. Virol. 75: 7692-7702 [Abstract] [Full Text]  
  • Arroyo, J., Guirakhoo, F., Fenner, S., Zhang, Z.-X., Monath, T. P., Chambers, T. J. (2001). Molecular Basis for Attenuation of Neurovirulence of a Yellow Fever Virus/Japanese Encephalitis Virus Chimera Vaccine (ChimeriVax-JE). J. Virol. 75: 934-942 [Abstract] [Full Text]  
  • McAllister, A., Arbetman, A. E., Mandl, S., Peña-Rossi, C., Andino, R. (2000). Recombinant Yellow Fever Viruses Are Effective Therapeutic Vaccines for Treatment of Murine Experimental Solid Tumors and Pulmonary Metastases. J. Virol. 74: 9197-9205 [Abstract] [Full Text]  
  • van der Most, R. G., Murali-Krishna, K., Ahmed, R., Strauss, J. H. (2000). Chimeric Yellow Fever/Dengue Virus as a Candidate Dengue Vaccine: Quantitation of the Dengue Virus-Specific CD8 T-Cell Response. J. Virol. 74: 8094-8101 [Abstract] [Full Text]  
  • Guirakhoo, F., Weltzin, R., Chambers, T. J., Zhang, Z.-X., Soike, K., Ratterree, M., Arroyo, J., Georgakopoulos, K., Catalan, J., Monath, T. P. (2000). Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates. J. Virol. 74: 5477-5485 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»